PROVE2: Phase II study of VX950 (telaprevir) in combination with peginterferon alfa2a with or without ribavirin in subjects with chronic hepatitis C, first interim analysis

被引：0
|
作者：
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Pol, Stanislas
Goeser, Tobias
Bronowicki, Jean-Pierre
Gharakhanian, Shahin
Devonish, Desiree
Kauffman, Robert
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
机构：
[1] Hop Henri Mondor, AP HP, Hepatogastroenterol Serv, F-94010 Creteil, France
[2] Med Univ Vienna, Vienna, Austria
[3] Royal Free Hosp, Ctr Hepatol, London NW3 2QG, England
[4] Necker Cochin Hosp, AP HP, Liver Unit, Paris, France
[5] Univ Cologne, Cologne, Germany
[6] Nancy Univ Hosp Ctr, CHU, Nancy, France
[7] Vertex Pharmaceut Inc, Med Dev Grp, Cambridge, MA USA
[8] Hop Henri Mondor, AP HP, Dept Bacterol & Virol, F-94010 Creteil, France
[9] Saarland Univ Hosp, Internal Med Clin 2, Homburg, Germany
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
80
引用
收藏
页码：268A / 269A
页数：2
相关论文
共 50 条
  • [31] Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naive Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE 1, PROVE2, PROVE3 and Study 107
    Shiffman, Mitchell
    Berg, Thomas
    Muir, Andrew
    McHutchison, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    Bengtsson, Leif
    Adda, Nathalie
    George, Shelley
    Kauffman, Robert
    Poordad, Fred
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S102 - S102
  • [32] Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C
    Missiha, SB
    Heathcote, EJ
    Arenovich, T
    Khan, K
    GASTROENTEROLOGY, 2005, 128 (04) : A683 - A684
  • [33] VIRAL RESPONSES IN AFRICAN-AMERICANS, LATINOS AND CAUCASIANS IN THE US PHASE 2 STUDY (PROVE1) OF TELAPREVIR WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAME GENOTYPE 1-INFECTED SUBJECTS WITH HEPATITIS C
    Muir, Andrew J.
    Lawitz, Eric J.
    McHutchison, John G.
    Gordon, Stuart C.
    Jacobson, Ira M.
    Adiwijaya, Bambang S.
    Bengtsson, Leif
    McNair, Lindsay
    Rodriguez-Torres, Maribel
    HEPATOLOGY, 2008, 48 (04) : 1131A - 1132A
  • [34] Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
    Marcellin, Patrick
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    Serfaty, Lawrence
    De Backer, Koen
    Van Heeswijk, Rolf
    Luo, Donghan
    Picchio, Gaston
    Beumont, Maria
    GASTROENTEROLOGY, 2011, 140 (02) : 459 - U159
  • [35] Robust synergistic antiviral effect of R1626 in combination with peginterferon alfa-2a (400), with or without ribavirin - Interim analysis results of Phase 2a study
    Pockros, Paul J.
    Nelson, David
    Godofsky, Eliot
    Rodriguez-Torres, Maribel
    Everson, Greg
    Fried, Michael W.
    Ghalib, Reem H.
    Harrison, Stephen A.
    Nyberg, Lisa M.
    Shiffman, Mitchell L.
    Hill, George Z.
    Chan, Anna
    HEPATOLOGY, 2007, 46 (04) : 311A - 311A
  • [36] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR-ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1 HEPATITIS C: WEEK 4 INTERIM RESULTS
    Forns, Xavier
    Marcellin, Patrick
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Vangeneugden, Tony J.
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1137A
  • [37] The cost-effectiveness analysis of peginterferon alfa-2a and ribavirin versus interferon alfa-2b and ribavirin in chronic hepatitis C in Poland
    Orlewska, E
    Juszczyk, J
    VALUE IN HEALTH, 2003, 6 (06) : 749 - 750
  • [38] Response-guided Telaprevir Combination Treatment in Genotype 1 Chronic Hepatitis C Patients who had Prior Relapse to Peginterferon Alfa-2a/Ribavirin
    Muir, Andrew
    Adiwijaya, Bambang
    Poordad, Fred
    Gritz, Linda
    Bengtsson, Leif
    Luo, Don
    Picchio, Gaston
    Kauffman, Robert
    Adda, Nathalie
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S114 - S115
  • [39] RELEVANCE BETWEEN FIBROSIS AND RESPONSE TO TREATMENT WITH PEGINTERFERON ALFA2A VS ALFA2B WITH RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE 3 PATIENTS. RANDOMIZED OPEN LABEL STUDY
    Kolakowska-Rzadzko, Anna
    Berok, Hanna
    Wasilewski, Marek
    Horbon, Andrzej
    HEPATOLOGY, 2008, 48 (04) : 878A - 878A
  • [40] REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY
    Mauss, S.
    Boeker, K. H. W.
    Eisenbach, C.
    Moeller, B.
    Moog, G.
    Lutz, T.
    Naumann, U.
    Christensen, S.
    Jung, M. -C.
    Teuber, G.
    Doss, M. Frank
    Schuchmann, M.
    Schott, E.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S357 - S358
12345